Faculty and Student Publications
Document Type
Article
Publication Date
12-1-2021
Abstract
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
Relational Format
journal article
Recommended Citation
Rebold, N., Morrisette, T., Lagnf, A. M., Alosaimy, S., Holger, D., Barber, K., Justo, J. A., Antosz, K., Carlson, T. J., Frens, J. J., Biagi, M., Kufel, W. D., Moore, W. J., Mercuro, N., Raux, B. R., & Rybak, M. J. (2021). Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections. Open Forum Infectious Diseases, 8(12), ofab554. https://doi.org/10.1093/ofid/ofab554
DOI
10.1093/ofid/ofab554
Accessibility Status
Searchable text